Nephrogenic Systemic Fibrosis in the Podiatric Patient

被引:2
|
作者
Freed, Lewis [1 ]
Hill, Josh [2 ]
Gooch, David [1 ]
机构
[1] E Valley Foot & Ankle Specialists, Mesa, AZ 85206 USA
[2] Univ Louisville Hosp, Jewish Hosp & St Marys Healthcare, Dept Podiatry & Orthoped, Louisville, KY USA
关键词
STAGE RENAL-DISEASE; OF-THE-LITERATURE; DERMOPATHY; GADOLINIUM; FAILURE; INVOLVEMENT; DISORDER; TISSUE;
D O I
10.7547/1020419
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Nephrogenic systemic fibrosis (NSF) is a severely debilitating disease that was first described in the literature by Cowper and colleagues in 2000. It is pertinent to the field of podiatry because patients with NSF first manifest cutaneous symptoms in the lower extremity in the form of fibrosing lesions. To date, these lesions have been documented only in people with moderate to severe kidney failure. There is speculation that gadolinium, used as a contrast agent for imaging, might be the inciting factor that triggers a cascade of events that results in the inappropriate fibrosis both in the dermis and in deeper tissues. Nephrogenic systemic fibrosis has been shown to cause these lesions in the lungs, pleura, diaphragm, myocardium, pericardium, and dura mater, the presence of which are typically indicative of severe progression of NSF. In cases where the lesions are manifest in the periarticular tissue, joint contractures and restricted range of motion can often result. We provide a quick synopsis of NSF, and a short case study that describes the authors' experience with one of their patients who requested a surgical consult as a result of being wheelchair-bound due to NSF's sequelae. (J Am Podiatr Med Assoc 102(5): 419-421, 2012)
引用
收藏
页码:419 / 421
页数:3
相关论文
共 50 条
  • [41] Gadolinium and nephrogenic systemic fibrosis
    Fisa Ramos, Ivan
    Soler, Ana
    Bonet, Teresa
    Escacena, Monica
    Duch, Jonathan
    IMAGEN DIAGNOSTICA, 2013, 4 (01): : 29 - 32
  • [42] Nephrogenic Systemic Fibrosis: Clinical Picture and Treatment
    Marckmann, Peter
    Skov, Lone
    RADIOLOGIC CLINICS OF NORTH AMERICA, 2009, 47 (05) : 833 - +
  • [43] Nephrogenic Systemic Fibrosis in Denmark - A Nationwide Investigation
    Elmholdt, Tina R.
    Olesen, Anne B. B.
    Jorgensen, Bettina
    Kvist, Stinne
    Skov, Lone
    Thomsen, Henrik S.
    Marckmann, Peter
    Pedersen, Michael
    PLOS ONE, 2013, 8 (12):
  • [44] The Diagnosis: Nephrogenic Systemic Fibrosis
    不详
    CUTIS, 2011, 87 (01): : 19 - 20
  • [45] Decorin Is Significantly Overexpressed in Nephrogenic Systemic Fibrosis
    Gambichler, Thilo
    Kreuter, Alexander
    Skrygan, Marina
    Burkert, Bjoern
    Altmeyer, Peter
    Schieren, Gisela
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 132 (01) : 139 - 143
  • [46] Nephrogenic Systemic Fibrosis Late Skin Manifestations
    Bangsgaard, Nannie
    Marckmann, Peter
    Rossen, Kristian
    Skov, Lone
    ARCHIVES OF DERMATOLOGY, 2009, 145 (02) : 183 - 187
  • [47] Nephrogenic Systemic Fibrosis Pathogenesis, Diagnosis, and Therapy
    Kribben, Andreas
    Witzke, Oliver
    Hillen, Uwe
    Barkhausen, Joerg
    Daul, Anton E.
    Erbel, Raimund
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (18) : 1621 - 1628
  • [48] The debate between gadolinium versus erythropoietin in a renal transplant patient with nephrogenic systemic fibrosis
    Hashemi, Pantea
    Sina, Bahram
    Rietkerk, William
    Safai, Bijan
    JOURNAL OF NEPHROLOGY, 2013, 26 (01) : 48 - 54
  • [49] Validation of a Screening Instrument for Nephrogenic Systemic Fibrosis
    Lima, Xinaida Taligare
    Alora-Palli, Maria Beatrice
    Kimball, Alexandra Boer
    Kay, Jonathan
    ARTHRITIS CARE & RESEARCH, 2013, 65 (04) : 637 - 642
  • [50] The extra miles on preventing nephrogenic systemic fibrosis
    Kartamihardja, A. Adhipatria P.
    Tsushima, Yoshito
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2019, 9 (11) : 1911 - 1913